Shares of LifeMD, Inc. (NASDAQ: LFMD - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company.
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of Atul Kavthekar as Chief Financial Officer, effective today. The Company also announced leadership changes to support its next phase of growth.
LifeMD is rated Buy, trading at a low 0.796x TTM sales, with upside if multiples revert. LFMD's strategic divestment of WorkSimpli refocused the business as a pure-play telehealth and pharmacy provider. The recent launch of the Wegovy pill will expand growth from its GLP-1 vertical.
Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page.
LifeMD, Inc. (LFMD) Q4 2025 Earnings Call Transcript
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.02 per share a year ago.
Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million. Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million.
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of March:
LifeMD remains a deeply undervalued telehealth stock, now trading with significant pessimism priced in after a 55% decline. LFMD's business model faces risks from slowing growth, legal issues, competition, and a disappointing WorkSimpli sale, but the fundamental story remains intact. Preferred shares yield just under 10% and offer lower risk, but I favor the common stock for its substantial upside potential at current prices.
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on March 9, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time.
LifeMD is rated a buy with an FY 2026 target price of ~$6, implying over 85% upside from current levels. LFMD's shift to a pure-play telehealth model, divesting WorkSimpli, and integrating in-house pharmacy capabilities are expected to drive growth and margin expansion. Regulatory approval for 503-A compounding pharmacy and the Novo Nordisk Wegovy partnership are highlighted as key catalysts for profitability and differentiation.
Avantor (NYSE: AVTR - Get Free Report) and LifeMD (NASDAQ: LFMD - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations. Insider and Institutional Ownership 95.1% of Avantor shares are owned
NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of LifeMD, Inc. (NASDAQ: LFMD) breached their fiduciary duties to shareholders.
Shares of LifeMD, Inc. (NASDAQ: LFMD - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to
New York, New York--(Newsfile Corp. - January 22, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of LifeMD, Inc. (NASDAQ: LFMD) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at LifeMD caused the company to misrepresent or fail to disclose that: (1) LifeMD's competitive position was materially overstated; (2) raising LifeMD's 2025 guidance was reckless because rising customer acquisition costs in LifeMD's RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound had not properly been accounted for; and (3) as a result, statements about LifeMD's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Concentra Group Holdings Parent (NYSE: CON - Get Free Report) and LifeMD (NASDAQ: LFMD - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership. Analyst Ratings This is a breakdown of
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced the closing of a new senior secured revolving credit facility (“RCF”) with Citizens Bank, N.A. (“Citizens”). The facility has a maturity date of January 2, 2029 and provides for up to $50 million of total availability consisting of $30 million of committed availability with an additional accordion option of up to $20 million. As of closing, no balance was drawn on the RCF as the Company believes its cash on hand and expected cash flow are sufficient to fund its organic growth initiatives.
Adds first and only FDA‑approved oral GLP‑1 to its virtual weight management offering, expanding access to affordable, branded treatment options Adds first and only FDA‑approved oral GLP‑1 to its virtual weight management offering, expanding access to affordable, branded treatment options
Eurofins Scient (OTCMKTS:ERFSF - Get Free Report) and LifeMD (NASDAQ: LFMD - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership. Analyst Ratings This is a summary of recent ratings
NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on January 15, 2026, to holders of record at the close of business on January 5, 2026.